A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Phase 3 Recruiting
530 enrolled
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Phase 3 Recruiting
670 enrolled
DeLLphi-312
Phase 3 Recruiting
330 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
MK-6070-003
Phase 1/2 Recruiting
170 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Phase 2 Recruiting
36 enrolled
SKB500 Combinations in Patients With Small Cell Lung Cancer
Phase 2 Recruiting
80 enrolled
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Phase 2 Recruiting
900 enrolled
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Phase 2 Recruiting
134 enrolled
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Phase 2 Recruiting
49 enrolled
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Phase 2 Recruiting
50 enrolled
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Phase 3 Recruiting
621 enrolled
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Phase 2 Recruiting
30 enrolled
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
Phase 2 Recruiting
32 enrolled
A Study of Ivonescimab in First-Line ES-SCLC
Phase 2 Recruiting
180 enrolled
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Phase 2 Recruiting
56 enrolled
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
Phase 2 Recruiting
37 enrolled
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Phase 1 Recruiting
48 enrolled
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/2 Recruiting
120 enrolled
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Phase 2 Recruiting
38 enrolled
PEERS
Phase 2 Recruiting
46 enrolled
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Phase 2 Recruiting
280 enrolled
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
Phase 2 Recruiting
45 enrolled
CARRY-ON
Phase 2 Recruiting
142 enrolled
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Recruiting
65 enrolled
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Phase 2 Recruiting
45 enrolled
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Phase 2 Recruiting
21 enrolled
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
Recruiting
1,430 enrolled
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2 Recruiting
80 enrolled
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
Phase NA Recruiting
38 enrolled
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Phase 2 Recruiting
40 enrolled
FIRST-NEC
Phase 2 Recruiting
80 enrolled
Serplulimab Combined With CCRT for LS-SCLC.
Phase 2 Recruiting
96 enrolled
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
Phase 2 Recruiting
104 enrolled
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Phase 1/2 Recruiting
57 enrolled
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Phase 2 Recruiting
61 enrolled
TESSERACT
Phase 1/2 Recruiting
18 enrolled
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Phase 2 Recruiting
30 enrolled
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Phase 1/2 Recruiting
45 enrolled
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Phase 2 Recruiting
62 enrolled
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Phase 3 Recruiting
1 enrolled
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Phase 2 Recruiting
40 enrolled